Use of indacaterol for the treatment of COPD: A pharmacokinetic evaluation

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 1, 2014, Pages 129-137

  Cazzola, Mario ^a   Calzetta, Luigino ^b   Page, Clive P ^c   Matera, Maria Gabriella ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Analytical methods; COPD; Indacaterol; Pharmacokinetics; Special populations

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DRUG METABOLITE; ERYTHROMYCIN; GLUCURONOSYLTRANSFERASE 1A1; INDACATEROL; KETOCONAZOLE; P26.9 PROTEIN; P30.3 PROTEIN; PLACEBO; PLASMA PROTEIN; PROTEIN P37; UNCLASSIFIED DRUG; VERAPAMIL;

AGE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ETHNICITY; GENDER; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; POTASSIUM BLOOD LEVEL; QT INTERVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR;

ANIMALS; BRONCHODILATOR AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 84890422504     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.865723     Document Type: Article

References (32)

1. Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013(19 Suppl 1):20-9
2. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci 2009;38:533-47
3. Baur F, Beattie D, Beer D, et al. The identification of indacaterol as an ultra long-Acting inhaled beta2-Adrenoceptor agonist. J Med Chem 2010;53:3675-84
4. Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 2002;41:19-30
5. Novartis. Indacaterol (QAB149) in Chronic Obstructive Pulmonary Disease (NDA 22-383). Briefing Document prepared by Novartis Pharmaceuticals for the Pulmonary-Allergy Drugs Advisory Committee meeting March 8 2011. Available from: Http://www.fda.gov/ downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/ Drugs/ Pulmonary-AllergyDrugs AdvisoryCommittee/UCM245639.pdf [Last accessed 25 August 2013
6. Center for Drug Evaluation and Research. Application number: 022383Orig1s000. Pharmacology review(s). Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/nda/ 2011/022383Orig1s000PharmR.pdf [Last accessed 25 August 2013
7. European Medicines Agency. Assessment Report for Onbrez Breezhaler. Procedure No. EMEA/H/C/001114. Available from: Http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Public-Assessment-report/human/ 001114/WC500053735. pdf [Last accessed 27 August 2013
8. Center for Drug Evaluation and Research. Application number: 022383Orig1s000. Clinical pharmacology and biopharmaceutics review(s). Available from: Http://www. accessdata.fda.gov/drugsatfda-docs/nda/ 2011/ 022383Orig1s000ClinPharmR.pdf [Last accessed 28 August 2013
9. Emotte C, Heudi O, Deglave F, et al. Validation of an on-line solid-phase extraction method coupled to liquid chromatography-Tandem mass spectrometry detection for the determination of Indacaterol in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2012;895-896:1-9
10. Kagan M, Dain J, Peng L, Reynolds C. Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos 2012;40:1712-22
11. Mueller S, Haeberlin B, Edge S. Comparison of performance characteristics for Foradil Aerolizer-And Foradil Concept1 (a new single dose dry powder inhaler) at different test flow rates. Respir Drug Deliv 2008;3:675-8
12. Perry S, Woessner R, Kaiser G, et al. Pharmacokinetics of indacaterol after single and multiple inhaled doses. Am J Respir Crit Care Med 2010;181:A4420
13. McKeage K. Indacaterol: A review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs 2012;72:543-63
14. Lock R, Price D, Khindri S, et al. Efficient deposition and absorption of orally inhaled indacaterol in the lungs [abstract no P252]. European Respiratory Society Annual Congress; 24-28 September 2011; Amsterdam
15. Aubier M, Duval X, Knight H, et al. Indacaterol, a novel once-daily beta2-Agonist, is effective and well tolerated on multiple dosing in patients with mild-To-moderate COPD. Eur Respir J 2005;26(Suppl):287S
16. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44
17. Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-Agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther 2011;49:153-61
18. Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010;104:1869-76
19. Hosoe M, Woessner R, Matsushima S, et al. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: A comparison of data from two randomized, placebo controlled studies. Clin Drug Invest 2011;31:247-55
20. Matsushima S, Matthews I, Woessner R, et al. Systemic pharmacokinetics of indacaterol, an inhaled once-daily longacting beta2-Agonist, in different ethnic populations. Int J Clin Pharmacol Ther 2012;50:545-56
21. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: A randomized, multidose, placebo-And positive-controlled, parallelgroup thorough QT study. BMC Pulm Med 2011;11:31
22. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
23. Perry S, Goldsmith P, Vaidyanathan S, et al. No significant clinical drug-drug interaction potential with indacaterol [abstract no P3985]. European Respiratory Society Annual Congress; 24-28 September 2011; Amsterdam
24. Vaisman N, Koren G, Goldstein D, et al. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 1987;111:914-17
25. Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003;38:843-53
26. Schmekel B, Borgstrom L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and nonsmokers. Thorax 1991;46:225-8
27. Hochhaus G, Schmidt E, Rominger KL, Mollmann H. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm Res 1992;9:291-7
28. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel longacting beta2-Agonist, on isolated human bronchi. Eur Respir J 2007;29:575-81
29. Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med 2013;107:107-11
30. García-Martín E, Canto G, Ag-undez JA. Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opin Drug Metab Toxicol 2013;9:1437-52
31. Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010;46:139-50
32. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92.